Helen Robinson

Helen Robinson

Company: Artios Pharma

Job title: Vice President of Biology


Exploring Polθ as a New DDR Target 5:00 pm

Discovery and preclinical development of first-in-class inhibitors for oncology in a PARP-resistant setting Leveraging synthetic lethality and understanding of the theta-mediated end joining (TMEJ) to determine a validated target Latest from the lab, clinical validation, and future directions Discussing how it will compare to PARP Dissecting how to leverage it as a novel target Combination…Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.